MONTHLY subcutaneous combination therapy achieves undetectable viral RNA and liver enzyme normalization in chronic hepatitis delta. Results from the randomized, open-label Phase 3 ECLIPSE 1 trial indicate that pairing the small interfering RNA elebsiran with the monoclonal antibody tobevibart produces substantial virologic and biochemical responses over 48 weeks. Because coinfection with hepatitis delta virus accelerates progression to cirrhosis and hepatic decompensation, durable viral suppression remains a primary therapeutic goal in hepatology practice.
Efficacy in Chronic Hepatitis Delta
The multicenter investigation enrolled 124 adults with chronic hepatitis delta receiving background nucleos(t)ide analog therapy, approximately 55% of whom had compensated cirrhosis at baseline. Investigators randomized participants in a 2:1 ratio to receive subcutaneous elebsiran 200 mg plus tobevibart 300 mg every four weeks or delayed treatment initiated at Week 12. At Week 48, 44% of patients in the immediate-treatment arm achieved the primary composite endpoint of undetectable hepatitis delta virus RNA alongside alanine aminotransferase normalization, compared with 0% in the delayed-treatment group at Week 12. All treated participants achieved a virologic response by Week 24, and 79% reached undetectable viral RNA by Week 48, including 85% of individuals with compensated cirrhosis and 73% of those without cirrhosis. Additionally, hepatitis B surface antigen levels declined below 10 IU/mL in 95% of treated patients.
Tolerability and Clinical Implications
Safety outcomes across the 48-week treatment window demonstrated favorable tolerability and high adherence. Every participant assigned to immediate combination therapy completed the full 48-week regimen without treatment interruptions or discontinuations. Most treatment-related adverse events were mild to moderate and transient, consisting primarily of flu-like symptoms following the initial dose that resolved within 24 to 48 hours. Investigators documented a single grade 3 treatment-related adverse event involving decreased neutrophil count, which resolved within 15 days. For physicians managing chronic hepatitis delta, a once-monthly subcutaneous regimen capable of suppressing viral replication and reducing hepatitis B surface antigen burden offers a promising clinical approach pending confirmatory Phase 3 readouts.
Reference
Reau N et al. Primary endpoint results of ECLIPSE 1: a randomized open-label phase 3 study evaluating efficacy and safety of elebsiran and tobevibart for chronic hepatitis delta. Presented at: The Liver Meeting; November 5–9, 2026; Denver, CO.